Case report and literature review of refractory hypoalbuminemic ascites caused by so-dium valproate

Update:Sep. 23, 2021Total Views:968Total Downloads:407 DownloadMobile

Author: Hui-Min YANG 1, 2 Si-Sun LIU 3 Fen WANG 3

Affiliation: 1. Department of Emergency, Jiangxi Maternal and Child Health Hospital, Nanchang 330006, China 2. Department of Emergency, Maternal and Child Health Affiliated Hospital of Nanchang University, Nanchang 330006, China 3. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Keywords: Sodium valproate Hypoproteinemia Ascites

DOI:10.12173/j.issn.1004-5511.202101042

Reference:Yang HM, Liu SS, Wang F. Case report and literature review of refractory hypoalbuminemic ascites caused by sodium valproate[J]. Yixue Xinzhi Zazhi, 2021, 31(5): 395-399. DOI: 10.12173/j.issn.1004-5511.202101042.[Article in Chinese]

  • Abstract
  • Full-text
  • Figures and Tables
  • References
Abstract

Sodium valproate is widely used in clinical practice as a broad-spectrum anti-epileptic. The common adverse reactions are nausea, vomiting, skin rash, ataxia and leukopenia. There are few reported cases of refractory hypoproteinemia ascites. We retrospectively analyzed the diagnosis and treatment of a case of refractory hypoalbuminemia ascites caused by sodium valproate in the First Affiliated Hospital of Nanchang University, aiming to provide clinician introduction with the benifit of our experience.

Full-text
Please download the PDF version to read the full text: download
References

1.   陈敏, 刘真真, 胡辉歌, 等. 疑难低蛋白血症的诊治[J]. 中华消化杂志, 2017, 37(7): 476-480. DOI: 10.3760/cma.j.issn.0254-1432.2017.07.011. [Chen M, Liu ZZ, Hu HG, et al. Diagnosis and treatment of difficult hypoproteinemia[J]. Chinese Journal of Digestion, 2017, 37(7): 476-480.]

2.   孙超, 郭欣, 许新华, 等. 低蛋白血症与临床各系统疾病转归的相关性研究进展[J]. 承德医学院学报, 2015, 32(5): 435-437. DOI: CNKI:SUN:CDYX.0.2015-05-034. [Sun C, Guo X, Xu XH, et al. Research progress on the correlation between hypoproteinemia and clinical disease outcome [J]. Journal of Chengde Medical College, 2015, 32(5): 435-437.]

3.   孟亚莉, 郑松柏. 老年人低蛋白血症研究进展[J]. 中华老年医学杂志, 2020, 39(2): 228-229. DOI: 10.3760/cma.j.issn.0254-9026.2020.02.024. [Meng YL, Zheng SB. Research progress of senile hypopro-teinemia[J]. Chinese Journal of Geriatrics, 2020, 39(2): 228-229.]

4.   Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance[J]. JPEN J Parenter Enteral Nutr, 2019, 43(2): 181-193. DOI: 10.1002/jpen.1451.

5.   周静. 癫痫患者172例丙戊酸钠血药浓度分析[J]. 临床合理用药杂志, 2021, 14(10): 147-149. DOI: 10.158 87/j.cnki.13-1389/r.2021.10.063. [Zhou J. Analysis of blood concentration of sodium valproate in 172 patients with epilepsy[J]. Journal of Clinical Rational Drug Use, 2021, 14(10): 147-149.]

6.   李璐, 王占璋, 胡晋卿, 等. 230例丙戊酸盐类药物不良反应的临床分析[J]. 今日药学, 2020, 30(6): 412-414. DOI: 10.12048/j.issn.1674-229X.2020.06.010. [Li L, Wang ZZ, Hu JQ, et al. Clinical analysis of 230 cases of adverse drug reactions caused by valproic acid salts[J]. Pharmaceutical Today, 2020, 30(6): 412-414.]

7.   Peng X, Yan Y, Chen R, et al. Long-term safety, tolerability, and efficacy of magnesium valproate versus sodium valproate in acute seizures[J]. Curr Med Res Opin, 2020, 36(2): 271-276. DOI: 10.1080/03007995.2019.1699520.

8.   谭亚倩, 王占璋, 卢浩扬, 等. 丙戊酸钠临床药物不良反应分析及合理用药[J]. 中国临床药理学杂志, 2020, 36(16): 2501-2503. DOI: 10.13699/j.cnki.1001-6821. 2020.16.032. [Tan YQ, Wang ZZ, Lu HY, et al. Adverse drug reaction analysis and rational drug use of sodium valproate[J]. Chinese Journal of Clinical Pharmacol-ogy, 2020, 36(16): 2501-2503.]

9.   张永生. 丙戊酸钠用于临床治疗的不良反应及合理用药分析[J]. 医学食疗与健康, 2021, 19(4): 54-55. [Zhang YS. Adverse reactions of sodium valproate in clinical treatment and rational drug use[J]. Medical Diet and Health, 2021, 19(4): 54-55.]

10.  岑俊红. 丙戊酸钠血药浓度与抗癫痫疗效及不良反应关系研究[J]. 中外女性健康研究, 2018, (18): 64-99. DOI: 10.3969/j.issn.2096-0417.2018.18.039. [Cen JH. Study on the relationship between serum concentration of sodium valproate and antiepileptic efficacy and adverse reactions[J]. Chinese and Foreign Women Health Research, 2018, (18): 64-99.]

11.  郝玉竹, 陈淑宝, 刘铁桥. 丙戊酸钠相关外周性水肿1例[J]. 中国新药与临床杂志, 2020, 39(3): 191-192. DOI: 10.14109/j.cnki.xyylc.2020.03.13. [Hao YZ, Chen SB, Liu TQ. A case of peripheral edema associated with sodium valproate [J]. Chinese Journal of New Drugs and Clinical, 2020, 39(3): 191-192.]

12.  Kim HK, Kim DY, Bae E, et al. Adverse skin reactions with antiepileptic drugs using korea adverse event reporting system database, 2008-2017[J]. J Korean Med Sci, 2020, 35(4): e17. DOI: 10.3346/jkms.2020.35.e17.

13.  Drisaldi A, Weeda E, Neyens R, et al. Accuracy of valproic acid concentration correction based on se-rum albumin[J]. Neurocrit Care, 2019, 30(2): 301-306. DOI: 10.1007/s12028-018-0627-4.

14.  Buoli M, Serati M, Botturi A, et al. The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data[J]. Drugs R D, 2018, 18(1): 1-5. DOI: 10.1007/s40268-017-0224-6.

15.  Abosi O, Lopes S, Schmitz S, et al. Cardiometabolic effects of psychotropic medications[J]. Horm Mol Biol Clin Investig, 2018, 36(1). DOI: 10.1515/hmbci-2017-0065.

16.  Woo PY, Woo AW, Lam SW, et al. Incidence, presentation, and risk factors for sodium valproate-associated hyperammonemia in neurosurgical patients: a prospective, observational study[J]. World Neurosurg, 2020, 144: e597-e604. DOI: 10.1016/j.wneu.2020.09.027.

17.  Fricke-Galindo I, Jung-Cook H, LLerena A, et al. Farmacogenética de reacciones adversas a fármacos antiepilépticos[J]. Neurología, 2018, 33(3): 165-176. DOI: 10.1016/j.nrl.2015.03.005.

18.  Fadare JO, Sunmonu TA, Bankole IA, et al. Medication adherence and adverse effect profile of antie-pi-leptic drugs in Nigerian patients with epilepsy[J]. Neurodegener Dis Manag, 2018, 8(1): 25-36. DOI: 10.2217/nmt-2017-0044.

19.  刘欢. 丙戊酸钠缓释片治疗老年癫痫的临床疗效[J]. 临床合理用药杂志, 2021, 14(15): 68-70. DOI: 10.1588 7/j.cnki.13-1389/r.2021.15.023. [Liu H. Clinical efficacy of sodium valproate sustained-release tablets in the treatment of senile epilepsy[J]. Chinese Journal of Clinical Rational Drug Use, 2021, 14(15): 68-70.]

20.  张晓毅, 许莉, 常凯琴, 等. 丙戊酸钠致不良反应40例临床分析[J]. 中国疗养医学, 2019, 28(5): 471-473. DOI: 10.13517/j.cnki.ccm.2019.05.008. [Zhang XY, Xu L, Chang KQ, et al. Clinical analysis of 40 cases of ad-verse reactions caused by sodium valproate[J]. Chinese Journal of Convalescent Medicine, 2019, 28(5): 471-473.]

21.  Janković SM, Janković SV. Lessons learned from the discovery of sodium valproate and what has this meant to future drug discovery efforts?[J]. Expert Opin Drug Discov, 2020, 15(11): 1355-1364. DOI: 10.1080/17460441.2020. 1795125.

22.  Dumas C, Jamilloux Y, Bienvenu AL. Sodium valproate and dysmegakaryocytopoiesis[J]. Br J Haematol, 2019, 186(2): 204. DOI: 10.1111/bjh.15974.

23.  Malik S, Lally J, Ajnakina O, et al. Sodium valproate and clozapine induced neutropenia: a case control study using register data[J]. Schizophr Res, 2018, 195: 267-273.DOI: 10.1016/j.schres.2017.08.041.

24.  Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid[J]. Clinical Biochemistry, 2013, 46(15): 1323-1338. DOI: 10.1016/j.clinbiochem.2013.06.012.

25.  Kumar R, Vidaurre J, Gedela S. Valproic acid-induced coagulopathy[J]. Pediatr Neurol, 2019, 98: 25-30.DOI: 10.1016/j.pediatrneurol.2019.04.019.

26.  卓实, 单丽. 丙戊酸钠所致不良反应60例临床分析[J]. 临床合理用药杂志, 2016, 9(4): 99-100. DOI: CNKI:SUN:PLHY.0.2016-04-065. [Zhuo S, Shan L. Clinical analysis of 60 cases of adverse reactions caused by sodium valproate[J]. Journal of Clinical Rational Drug Use, 2016, 9(4): 99-100.]

27.  郭晓宁, 金戈. 丙戊酸钠致不良反应16例分析[J]. 中国医院用药评价与分析, 2016, 16(2): 240-242. DOI: 10.14009/j.issn.1672-2124.2016.02.034. [Guo XN, Jin G. Analysis of 16 cases of adverse reactions caused by sodium valproate[J]. Evaluation and Analysis of Drug Use in Chinese Hospitals, 2016, 16(2): 240-242.]

Hot Papers